Biofrontera earnings release, May 14, 2026

Biofrontera Inc. (BFRI) · Form 8-K, Item 2.02 · Filed · SEC filing

Biofrontera

Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update

Woburn,

MA (May 14, 2026) (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ: BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update.

First

Quarter Financial Highlights

Recent

Operational Highlights

Hermann

Luebbert, Chief Executive Officer and Chairman of Biofrontera Inc., stated: “The first quarter of 2026 marks the first full quarter under our new cost structure following the Strategic Transaction, and the results speak clearly. Revenue grew 17% year over year, gross margins expanded to approximately 80%, and our cash consumption was near zero—a dramatic improvement from $4.1 million of cash consumption in the prior-year quarter. Our results were further driven by continued commercial momentum leading to significant uptake of the Ameluz PDT platform by dermatologists and their patients.

At the same time, our clinical pipeline continues to advance at an accelerated pace. With a PDUFA date for sBCC in September 2026, positive

Phase 3 results in AK on neck/trunk and extremities, and encouraging Phase 2b data in acne, we have multiple near-term catalysts that could meaningfully expand the commercial opportunity for the Ameluz platform.

We remain focused on our goal of reaching sustained profitability and cash-flow breakeven while setting the foundation for medium to long-term growth, and I believe we are well positioned to help our customers and their patients and build long-term value for our shareholders.”

First

Quarter Financial Results

Total revenues for the first quarter of 2026 were $10.1 million compared with $8.6 million for the first quarter of 2025. The 17% year-over-year growth was primarily driven by approximately 16% growth in the number of Ameluz units sold and a price increase implemented in the fourth quarter of 2025.

Gross profit margin in the first quarter of 2026 was approximately 80% compared to approximately 62% in Q1 2025. Cost of revenues, related party decreased by approximately 40% year over year, driven by the transition from the transfer pricing model under the prior license and supply agreement to the significantly lower earnout structure in place following the Strategic Transaction. The Company recognized

$1.2 million in earnout expense during the quarter.

Total operating expenses were $14.4 million for the first quarter of 2026 compared with $13.1 million for the first quarter of 2025.

Selling, general and administrative expenses were $11.0 million for the first quarter of 2026 compared with $8.7 million for the first quarter of 2025. The increase was primarily driven by higher selling and marketing costs reflecting lower sales team turnover during the period leading to the full deployment of the direct sales team, increased legal expenses associated with ongoing patent-related claims, and manufacturing-related costs of $0.6 million assumed in connection with the Strategic Transaction.

Research and development expenses were $0.9 million for the first quarter of 2026 compared with $1.2 million for the first quarter of 2025. The decrease was primarily attributable to certain clinical trials reaching substantial completion.

The net loss for the first quarter of 2026 was $4.8 million, or $0.41 per share, compared with a net loss of $4.2 million, or $0.47 per share, for the prior-year quarter. The net loss comparison was impacted by a $0.8 million swing in the non-cash change in fair value of warrant liabilities.

Adjusted

EBITDA for the first quarter of 2026 was $(3.6) million compared with $(4.4) million for the first quarter of 2025, an improvement of approximately $0.8 million. Adjusted EBITDA margin improved to (35.3)% from (51.0)% in the prior-year quarter. We look at Adjusted EBITDA, a non-GAAP financial measure, as an indication of ongoing operations, defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items.

Please refer to the table below which presents a GAAP to non-GAAP reconciliation of Adjusted EBITDA for the first quarters of 2026 and 2025.

Conference

Call Details

Conference call: Thursday, May 14, 2026 at 11:00 AM ET

About

Biofrontera Inc.

Biofrontera

Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with photodynamic therapy (PDT). The Company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, and in development for additional indications. For more information, visit www.biofrontera-us.com and follow Biofrontera on LinkedIn and X.

Contacts

Investor Relations

Ben

Shamsian

Lytham

Partners

646-829-9701 shamsian@lythampartners.com

Forward-Looking

Statements

Financial statements

Income Statement

BIOFRONTERA INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts and number of shares)

Three Months Ended March 31, 2026 (Unaudited)Three Months Ended March 31, 2025 (Unaudited)
Product revenues, net10,0848,588
Operating expensesCost of revenues, related party1,8313,075
Operating expensesCost of revenues, other285193
Operating expensesSelling, general and administrative10,9948,653
Operating expensesSelling, general and administrative, related party27
Operating expensesPatent remediation expense392
Operating expensesResearch and development9001,207
Operating expensesTotal operating expenses14,40413,135
Operating expensesLoss from operations-4,320-4,547
Other income (expense)Change in fair value of warrant liabilities-219548
Other income (expense)Interest expense, net-125-106
Other income (expense)Other expense, net-88-99
Other income (expense)Total other income (expense)-432343
Other income (expense)Loss before income taxes-4,752-4,204
Other income (expense)Income tax benefit-1
Other income (expense)Net loss-4,752-4,203
Loss per common share:Basic and diluted-0.41-0.47
Weighted-average common shares outstanding:Basic and diluted11,683,3238,873,932

Income Statement

BIOFRONTERA INC. GAAP TO NON-GAAP ADJUSTED EBITDA RECONCILIATION (In thousands) (in thousands)

Three Months Ended March 31, 2026 (Unaudited)Three Months Ended March 31, 2025 (Unaudited)
Net loss-4,752-4,203
Interest expense, net125106
Income tax expense-1
Depreciation and amortization5529
EBITDA-4,572-4,069
Change in fair value of warrant liabilities219-548
Stock-based compensation342239
Patent remediation - inventory write-down58
Patent remediation expense392
Adjusted EBITDA-3,561-4,378
Adjusted EBITDA margin-35.3%-51.0%

Balance Sheet

December 31, 2025 — BIOFRONTERA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value and share amounts)

March 31, 2026 (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents6,3176,392
Current assets:Investment, related party99
Current assets:Accounts receivable, net3,8797,291
Current assets:Inventories1,2311,426
Current assets:Prepaid expenses and other current assets1,0622,279
Current assets:Other assets, related party661686
Current assets:Total current assets13,15918,083
Current assets:Inventories, long term3,5913,729
Current assets:Property and equipment, net2,1752,158
Current assets:Operating lease right-of-use assets2,8951,584
Current assets:Intangible assets, net2,6092,650
Current assets:Other assets358360
Current assets:Total assets24,78728,564
Current liabilities:Accounts payable3,6341,855
Current liabilities:Accounts payable, related parties, net1,3154,811
Current liabilities:Operating lease liabilities506332
Current liabilities:Accrued expenses and other current liabilities5,4684,897
Current liabilities:Total current liabilities10,92311,895
Long-term liabilities:Convertible notes payable, net4,7194,589
Long-term liabilities:Warrant liabilities570351
Long-term liabilities:Operating lease liabilities, non-current2,4991,240
Long-term liabilities:Other liabilities69
Long-term liabilities:Total liabilities18,71718,084
Long-term liabilities:Total stockholders’ equity6,07010,480
Long-term liabilities:Total liabilities and stockholders’ equity24,78728,564

Cash Flow

BIOFRONTERA INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In Thousands) (in thousands)

Three Months Ended March 31, 2026 (Unaudited)Three Months Ended March 31, 2025 (Unaudited)
Cash flows from operating activities:Net loss-4,752-4,203
Adjustments to reconcile net loss to cash flows used in operations:Depreciation and amortization5529
Adjustments to reconcile net loss to cash flows used in operations:Reduction in the carrying amount of right-of-use assets132190
Adjustments to reconcile net loss to cash flows used in operations:Stock-based compensation342239
Adjustments to reconcile net loss to cash flows used in operations:Non-cash interest expense130119
Adjustments to reconcile net loss to cash flows used in operations:Allowance for credit losses-1-46
Adjustments to reconcile net loss to cash flows used in operations:Change in fair value of warrant liabilities219-548
Adjustments to reconcile net loss to cash flows used in operations:Loss from termination of operating leases1
Changes in operating assets and liabilities:Accounts receivable3,4131,330
Changes in operating assets and liabilities:Other receivables, related party1
Changes in operating assets and liabilities:Prepaid expenses and other assets1,219-224
Changes in operating assets and liabilities:Other assets, related party25
Changes in operating assets and liabilities:Inventories307119
Changes in operating assets and liabilities:Accounts payable1,7801,444
Changes in operating assets and liabilities:Accounts payable, related parties, net-3,497-2,694
Changes in operating assets and liabilities:Operating lease liabilities-10-179
Changes in operating assets and liabilities:Accrued expenses and other liabilities566307
Changes in operating assets and liabilities:Cash flows used in operating activities-70-4,117
Cash flows from investing activitiesPurchases of property and equipment-5-3
Cash flows from investing activitiesCash flows used in investing activities-5-3
Full release

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private

Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, in this press release, including statements regarding our strategy, future operations, regulatory process, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. The words “believe”,

“anticipate”, “intend”, “expect”, “target”, “goal”, “estimate”,

“plan”, “assume”, “may”, “will”, “predict”, “project”, “would”,

“could” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements... (truncated)read this press release and any documents referenced herein completely and with the understanding that our actual future results may be materially different from what we expect. While we have based these forward-looking statements on our current expectations and projections about future events, we may not actually achieve the plans, intentions or expectations disclosed in or implied by our forward-looking statements, and you should not place undue reliance on our forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions about us and accordingly, actual results or events could differ materially from the plans, intentions and expectations disclosed in or implied by the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: our ability to achieve and sustain profitability; our ability to compete effectively in selling our products; our ability to expand, manage and maintain our direct sales and marketing efforts, including our ability to obtain the financing to develop our marketing strategy, if needed; changes in our relationship with our manufacturing partners and the possible impact of tariffs; our ability to manufacture our products; our ability to adequately protect our intellectual property and operate the business without infringing upon the intellectual property rights of others; our actual financial results may vary significantly from forecasts and from period to period; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; market risks regarding consolidation and group purchasing organizations

(“GPOs”) in the healthcare industry; the willingness of healthcare providers to purchase our products if coverage, reimbursement and pricing from third-party payors for our products, or procedures using our products significantly declines; our ability to market, commercialize, achieve market acceptance for and sell our products; the fact that product quality issues or product defects may harm our business; any claims brought against the Company, including but not limited to product liability claims, claims of patent infringement, or claims challenging the validity of our intellectual property; our ability to maintain compliance with The Nasdaq Stock Market, LLC continued listing standards; our ability to comply with the requirements of being a public company; the progress, timing and completion of research, development and preclinical studies and clinical trials for our products; our ability to obtain and maintain the regulatory approvals necessary for the marketing of our products in the United States; and other factors that may be disclosed in the Company’s filings with the Securities and Exchange Commission (“SEC”), which can be obtained on the SEC website at www.sec.gov.

Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Any forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this press release, except as required by applicable law. Investors should evaluate any statements made by us in light of these important factors.

(Tables follow)

BIOFRONTERA

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Biofrontera earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.